Distributional burden of the English urology elective waiting list after the 2024 reporting reset

Headline referral to treatment metrics can conceal where waiting-list mass lies. This study quantified the distributional and operational burden of the English C_101 Urology Service waiting list in the post-reset series, defined as April 2024 onward after consultant-led community service pathways were excluded from RTT submissions. A population-level analysis used all public NHS England Commissioner RTT incomplete-pathway workbooks from April 2024 to February 2026 and February 2026 flow workbooks. Outcomes included list size, 18-week performance, long-wait tails, the integer 92% standard gap, pathway-weeks beyond 18 weeks, flow balance and cross-specialty ranks. Trends used heteroskedasticity-and-autocorrelation-consistent regression. National 2019–2023 trends were shown descriptively but were not combined with the post-reset models. In February 2026, 385,949 urology pathways were incomplete; 246,524 (63.9%) were within 18 weeks and 139,425 (36.1%) were beyond 18 weeks. The integer gap to the 92% standard was 108,550. There were 6,799 pathways beyond 52 weeks, 448 beyond 65 weeks and 91 beyond 78 weeks. From April 2024, total incomplete pathways fell by 7.8%, pathways beyond 52 weeks by 63.9% and the 92nd-percentile wait by 6.4 weeks. Urology ranked seventh of 23 treatment functions by incomplete pathways and by 52-week burden. Its 63.9% within-18-week performance was above the estimated national 62.6%, although both were below the 65% interim benchmark. The long-wait tail contracted substantially, but a large operational standard gap remained. Aggregate C_101 pathways do not identify indication, urgency, cancer status or clinical outcomes; distributional auditing should therefore complement, not replace, patient-level clinical prioritisation.